# Project 1: Developing MRD-based therapeutic strategy in newly diagnosed multiple myeloma

> **NIH NIH P01** · DANA-FARBER CANCER INST · 2024 · $189,390

## Abstract

Project Summary – Project 1 CHU-Toulouse / DFCI
To improve overall outcome in multiple myeloma (MM), period this project in the current funding achieved three
major goals: 1: Defined the role of transplant in the era of novel agents with long term maintenance; 2:
Established the feasibility of measuring minimal residual disease (MRD) at 10-6 sensitivity, and demonstrated its
significant impact on prolongation of PFS irrespective of the type of treatment used; and 3) Demonstrated that
quadruplet therapies achieve high frequency of MRD negative response. In this renewal application, we now
propose to build upon our highly successful collaborative clinical study to address the next most important
question, whether high-dose therapy (HDT) can still provide benefit in patients achieving MRD negative status.
We hypothesize that quadruplet therapy followed by ASCT will achieve deeper MRD negative status (10-6), and
that sustained MRD negativity will be of therapeutic importance. Our proposed study will: 1) define the role of
ASCT in MM in the context of quadruplet induction therapy; determine whether ASCT further decreases tumor
burden, increases MRD negativity rates (NGS, 10-6), and improves patient outcome; and define whether
achieving early, late, and sustained MRD negativity impacts clinical outcome (Sp Aim 1). We will conduct a large
(n=716) study using induction therapy with isatuximab, carfilzomib, lenalidomide and dexamethasone (IsaKRD)
and then randomize those patients who are MRD negative to either further IsaKRD versus HDT. In Specific Aim
2, we will redefine new risk stratification incorporating MRD status and modern biochemical, genomic,
epigenomic, and immune and microenvironmental correlates. Our proposed study will determine the impact of
MRD informing prognosis and therapy.
.

## Key facts

- **NIH application ID:** 10894593
- **Project number:** 5P01CA155258-12
- **Recipient organization:** DANA-FARBER CANCER INST
- **Principal Investigator:** herve Avet loiseau
- **Activity code:** P01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $189,390
- **Award type:** 5
- **Project period:** 2011-12-01 → 2028-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10894593

## Citation

> US National Institutes of Health, RePORTER application 10894593, Project 1: Developing MRD-based therapeutic strategy in newly diagnosed multiple myeloma (5P01CA155258-12). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10894593. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*